Haloperidol
- CAS No.
- 52-86-8
- Chemical Name:
- Haloperidol
- Synonyms
- ALDO;Haldol;Dihydrohaloperidol;Haloperidol for system suitability;4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one;Dozic;Halol;r1625;Linton;Pernox
- CBNumber:
- CB7774829
- Molecular Formula:
- C21H23ClFNO2
- Molecular Weight:
- 375.86
- MOL File:
- 52-86-8.mol
- MSDS File:
- SDS
- Modify Date:
- 2023/7/21 17:23:12
Melting point | 152 °C |
---|---|
Boiling point | 529.0±50.0 °C(Predicted) |
Density | 1.1820 (estimate) |
Flash point | 9℃ |
storage temp. | 2-8°C |
solubility | 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.39 mg/mL |
form | powder |
pka | 8.3(at 25℃) |
color | white |
Water Solubility | 2.058mg/L(22.5 ºC) |
Merck | 14,4598 |
BCS Class | 4/3 |
CAS DataBase Reference | 52-86-8(CAS DataBase Reference) |
NIST Chemistry Reference | Haloperidol(52-86-8) |
EPA Substance Registry System | Haloperidol (52-86-8) |
SAFETY
Risk and Safety Statements
Symbol(GHS) | GHS06,GHS08 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Signal word | Danger | |||||||||
Hazard statements | H301-H315-H317-H319-H335-H361 | |||||||||
Precautionary statements | P201-P202-P280-P301+P310-P302+P352-P305+P351+P338 | |||||||||
Hazard Codes | T,F | |||||||||
Risk Statements | 60-61-25-36/37/38-43-39/23/24/25-23/24/25-11 | |||||||||
Safety Statements | 53-26-36/37/39-45-36/37-16 | |||||||||
RIDADR | UN 2811 6.1/PG 3 | |||||||||
WGK Germany | 3 | |||||||||
RTECS | EU1575000 | |||||||||
HazardClass | 6.1(b) | |||||||||
PackingGroup | III | |||||||||
HS Code | 2933399090 | |||||||||
Toxicity | LD50 orally in rats: 165 mg/kg (Goldenthal); i.p. in mice: 60 mg/kg (Collins, Horlington) | |||||||||
NFPA 704 |
|
Haloperidol price More Price(7)
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
Sigma-Aldrich(India) | H1512 | Haloperidol powder | 52-86-8 | 5G | ₹12329.68 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | PHR1724 | Haloperidol Pharmaceutical Secondary Standard; Certified Reference Material | 52-86-8 | 400MG | ₹13574.55 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | H1512 | Haloperidol powder | 52-86-8 | 10G | ₹21974.75 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | H1512 | Haloperidol powder | 52-86-8 | 25G | ₹47586.7 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | H-030 | Haloperidol solution 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material, Cerilliant? | 52-86-8 | 1ML | ₹3311.7 | 2022-06-14 | Buy |
Haloperidol Chemical Properties,Uses,Production
Description
Haloperidol is a butyrophenone with a long duration of action. It has lile α- adrenoceptor blocking activity and minimal effect on the cardiovascular system. It is an effective antiemetic but has a high incidence of extrapyramidal adverse effects. Haloperidol may be used in the short-term management of the acutely agitated patient (when sinister causes of confusion such as hypoxaemia and sepsis have been excluded) and in the management of delirium in ICU. The duration of action of haloperidol is approximately 24–48h.
Chemical Properties
White Crystalline Powder
Uses
Haloperidol is one of the most actively used modern neuroleptics. Its high antipsychotic activity is combined with a moderate sedative effect. It effectively stops various types of psychomotor excitement. It is used for schizophrenic psychoses, manic, paranoid, and delirious conditions, depression, psychomotor excitement of various origins, and for delirium and hallucinations of different origin.
Definition
ChEBI: A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
General Description
Haloperidol, 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4-fluorobutyrophenone (Haldol), is anodorless white to yellow crystalline powder. Haloperidol iswell and rapidly absorbed and has a high bioavailability. It ismore than 90% bound to plasma proteins. Haloperidol is excretedslowly in the urine and feces. About 30% of a dose isexcreted in urine and about 20% of a dose in feces via biliaryelimination,and only 1% of a dose is excreted as unchangeddrug in the urine.Haloperidol is a minor substrate of CYP1A2 and a major substrate of CYP2D6 and CYP3A4.CYP2D6 inhibitors may increase the levels/effects ofhaloperidol.Haloperidol may increase the levels/effects ofCYP2D6 substrates and it may decrease the bioactivationof CYP2D6 prodrugs substrates. Haloperidol also is a moderateinhibitor of CYP2D6 and CYP3A4. CYP3A4 inducersmay decrease the levels/effects of haloperidol, whereasCYP3A4 inhibitors may increase the levels/effects ofhaloperidol. Centrally acting acetylcholinesterase inhibitorsmay increase the risk of antipsychotic-related EPS. The precisemechanism of antipsychotic action is unclear but isconsidered to be associated with the potent DA D2receptor–blocking activity in the mesolimbic system and theresulting adaptive changes in the brain. Haloperidol is usedprimarily for the long-term treatment of psychosis and is especiallyuseful in patients who are noncompliant with theirdrug treatment.
Pharmaceutical Applications
Haloperidol is an analogue of the dopamine D2 receptor antagonist and is an older antipsychotic drug. The drug is used in the treatment of schizophrenia, a neuropsychiatric disorder. In general, antipsychotic drugs work by blocking the dopamine D2 receptors.
Haloperidol is such an antipsychotic drug, which was developed in the 1950s and entered the clinic soon after that. Its use is limited by the high incidence of extrapyramidal symptoms (movement disorders caused by drugs affecting the extrapyramidal system, a neural network which is part of the motor system). Nevertheless, haloperidol may be used for the rapid control of hyperactive psychotic states and is popular for treating restlessness in the elderly.
Biological Activity
Dopamine antagonist with selectivity for D 2 -like receptors (K i values are 1.2, ~ 7, 2.3, ~ 80 and ~ 100 nM for D 2 , D 3 , D 4 , D 1 and D 5 receptors respectively). Subtype-selective NMDA antagonist.
Haloperidol Preparation Products And Raw materials
Raw materials
1of2
chevron_rightPreparation Products
Supplier | Tel | Country | ProdList | Advantage | Inquiry |
---|---|---|---|---|---|
KARPSCHEM LABORATORIES | +91-7249203006 +91-7249203006 | Maharashtra, India | 786 | 58 | Inquiry |
Vamsi Labs Ltd | +91-2172357274 +91-9891966300 | Maharashtra, India | 43 | 58 | Inquiry |
R L Fine Chem Pvt. Ltd | +91-8042488999 +91-8042488999 | Karnataka, India | 74 | 58 | Inquiry |
Rivashaa Agrotech Biopharma Pvt. Ltd. | +91-26463395 +91-7926462688 | Gujarat, India | 1615 | 58 | Inquiry |
Lanz Labs Pvt Ltd | +91-2226205525 +91-2226205525 | Maharashtra, India | 5 | 58 | Inquiry |
Humble Healthcare Limited | +91-9720093000 +91-8006400378 | Uttar Pradesh, India | 141 | 58 | Inquiry |
Ralington Pharma | +91-7948911722 +91-9687771722 | Gujarat, India | 1350 | 58 | Inquiry |
Globela Industry Pvt Ltd | +91-2616158000 +91-9998199919 | Gujarat, India | 98 | 58 | Inquiry |
Mankind Pharma Limited | +91-1146541111 +91-1146541111 | New Delhi, India | 23 | 58 | Inquiry |
RPG Life Sciences Ltd | +91-2266606375 +91-2266606375 | Maharashtra, India | 15 | 58 | Inquiry |
Supplier | Advantage |
---|---|
KARPSCHEM LABORATORIES | 58 |
Vamsi Labs Ltd | 58 |
R L Fine Chem Pvt. Ltd | 58 |
Rivashaa Agrotech Biopharma Pvt. Ltd. | 58 |
Lanz Labs Pvt Ltd | 58 |
Humble Healthcare Limited | 58 |
Ralington Pharma | 58 |
Globela Industry Pvt Ltd | 58 |
Mankind Pharma Limited | 58 |
RPG Life Sciences Ltd | 58 |
52-86-8(Haloperidol)Related Search:
1of4
chevron_right